Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup

Af­ter sev­en months on the mar­ket, Re­gen­eron’s Eylea HD is al­ready mak­ing strides with oph­thal­mol­o­gists.

Ac­cord­ing to Spher­ix Glob­al In­sights’ re­search, 81% of oph­thal­mol­o­gists who use Eylea HD to treat wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) are “high­ly sat­is­fied,” which tracks close­ly to the 87% who say the same about Roche and Genen­tech’s Vabysmo, which has been on the mar­ket for about 25 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.